It’s fitting that the investigators who developed a new CAR T-based treatment for glioblastoma called their treatment platform “CAR-TEAM” cells, as it took a true team effort to bring their concept from the lab to the clinic.
Cellular Immunotherapy Program
The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells.
Explore the Cellular Immunotherapy Program
Overview
The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.
Our objectives:
We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies.
- Bring together clinical researchers who administer, manage, and/or investigate immune effector cells as a therapeutic modality
- Enable translational research and collaboration
- Optimize immune monitoring and laboratory correlatives of clinical observations
- Promote cellular therapy education through education sessions
- Provide high quality care and management of patients receiving cellular therapies
- Obtain and maintain FACT accreditation for the administration of immune effector cells
- Invent and develop novel forms of cellular engineering that will become the next generation of immune cell therapies
Clinical Trials
View Cellular Therapy clinical trials.
CAR T-Cell Therapies
Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma (Breyanzi, Kymriah, Tecartus and Yescarta) and for adult patients with multiple myeloma (Abecma). Learn more.
TIL Therapy for Melanoma
Mass General Cancer Center is one of the first centers nationwide that offers FDA-approved Iovance TIL therapy (lifileucel) for patients with metastatic melanoma. Learn more.
CAR-T Therapy for Glioblastoma: INCIPIENT Clinical Trial
A research team from the Mass General Cancer Center recently conducted an early-stage trial of a new cell therapy for patients with recurrent glioblastoma. Preliminary results have shown remarkable initial responses among the first patients to receive the novel treatment. Learn more about the trial here and here.
If you are interested in learning more about the INCIPIENT clinical trial, please call 617-724-6226 or email carteamingbm@mgb.org. A member of our clinical team will contact you within 48 business hours.
Meet the Team
Lead by Marcela Maus, MD, PhD and Matthew Frigault, MD, the Cellular Immunotherapy Program brings together physicians and laboratory scientists focused on immune cell engineering and its clinical effects.
-
![]()
- Clinical Director, Cellular Therapy Service
- John and Ashley Ranelli Endowed Scholar in Cancer Innovation
- Assistant Professor of Medicine, Harvard Medical School
-
![]()
- Director, Cellular Immunotherapy Program
- Professor of Medicine, Harvard Medical School
Resources
Learn how gene and cell therapy research at Mass General Brigham is rapidly advancing.
Visit the Maus laboratory, view publications and meet the team.
CAR T-Cell Therapies
View CAR T-Cell Therapies.
TIL Therapy
Mass General is one of the first centers to offer TIL therapy for pts with melanoma.
Severe Immunotherapy Complications Service
Learn about Mass General's Severe Immunotherapy Complications Service.
Immune Monitoring Lab
Learn about the Immune Monitoring laboratory.
Cellular Therapy & Transplantation Lab
Learn about the Cellular Therapy & Transplantation Laboratory.
FACT Standards for Immune Effector Cells.
The why, what, and how of the new FACT standards for immune effector cells.
Contact the Cancer Center
Contact the Mass General Cancer Center to make an appointment or learn more about our programs.